Assertio Holdings, Inc.
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients and has a robust portfolio of branded prescription products in three areas: neurology, hospital and pain and inflammation. The Company has grown through business development including licensing, mergers, and acquisitions and is interested in products across all therapeutic areas, including our current focus.
Nasdaq: ASRT
IR Website: https://investor.assertiotx.com/overview/default.aspx
Headquarters: Lake Forest, IL
Content provided by Assertio Holdings Inc. on 9-28-22.
TALK TO MANAGEMENT
The Assertio management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Assertio is a diversified specialty pharmaceutical company that offers differentiated, branded prescription medicines to patients by leveraging its unique digital platform and strategy. This approach allows the company to seamlessly add additional assets and target several different therapeutic areas while leveraging its deep and proven experience managing brands. With our focus on generating cash and delivering best in class margins, we are primed to be a consolidator in this space.
Investor Presentation
Recent News
Assertio to Participate in the 2022 Lake Street BIG6 Conference
Sept 7, 2022
Assertio Announces Closing of $70 Million Convertible Senior Notes Offering
Aug 25, 2022
Assertio Announces Proposed Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024
Aug 22, 2022
Assertio Reports Second Quarter 2022 Financial Results
Aug 8, 2022
Assertio Holdings, Inc. To Report Second Quarter 2022 Financial Results on Monday, August 8, 2022
July 25, 2022
Management Overview
Dan A. Peisert
President, Chief Executive Officer & Director
Mr. Peisert has served as President, Chief Executive Officer, and Director of Assertio since December 2020. Mr. Peisert joined Assertio as Vice President, Business Development in September 2017 and previously held the roles of Senior Vice President, Business Development and Senior Vice President and Chief Financial Officer for the company.
Most recently he served in the position of Vice President of Concordia International Corp.’s US Legacy Pharmaceuticals business where he had full P&L responsibility for the business unit. Prior to this, he was Vice President, Business Development for Concordia and was responsible for executing on the strategic M&A plan. Previously, Mr. Peisert was Director, Finance and Business Development for Marathon Pharmaceuticals, a privately held specialty pharmaceutical company.
Prior to entering the pharmaceutical industry, he was a healthcare Equity Analyst and for Magnetar Capital and a Portfolio Manager for UBS O’Connor and began his career as an Auditor for Price Waterhouse Coopers.
Mr. Peisert holds a bachelor’s degree in business with an emphasis on accounting from the University of Minnesota
Paul Schwichtenberg
Senior Vice President, Chief Financial Officer
Mr. Schwichtenberg has served as Senior Vice President, Chief Financial Officer of Assertio since March 2021. Mr. Schwichtenberg joined Assertio as Vice President, Finance in April 2018 and has been instrumental in leading Assertio’s financial planning and analysis, financial reporting and controls, gross-to-net planning, risk management, business development due diligence, and modeling.
Most recently he served in the position of Director, Pricing and Planning at AbbVie, where he led the US Commercial Pricing Team of 63 professionals responsible for commercial, institutional and government contracting, government price reporting, financial reporting, and financial planning.
Prior to this, he was a Controller for Radio Flyer, Inc., and Takeda Pharmaceuticals, where he executed numerous enhancements to reporting technology to identify margin opportunities as well as integrated acquisitions across the consumer and pharmaceutical space.
Prior to entering the pharmaceutical industry, he was a senior auditor at Wolf & Company LLP. Mr. Schwichtenberg holds a bachelor’s degree in business administration from Roosevelt University and is a certified public accountant (CPA).
Bill Iskos
Senior Vice President, Operations
Mr. Iskos has served as Senior Vice President, Operations of Assertio since August 2021. Mr. Iskos is responsible for manufacturing, quality, supply chain, regulatory, business development related diligence, and alliance management of contracted services.
Mr. Iskos brings more than 28 years of diverse experience in pharmaceutical process research and development, clinical and commercial manufacturing, supply chain and logistics, and quality assurance of potent, specialty/orphan, generic, and biologic pharmaceutical products that incorporated several drug delivery technologies and devices. Prior to rejoining Assertio, Mr. Iskos served as a Principal CMC consultant for numerous life sciences companies, and held roles of increasing responsibility at Horizon Therapeutics, Abbott Laboratories, Pfizer, Pharmacia, and Searle. Throughout his career spanning the pharmaceutical life cycle, Mr. Iskos has built a proven ability to strategically develop and lead highly successful global operations groups across several operating models.
Mr. Iskos holds a bachelor’s degree in Chemical Engineering from the University of Illinois at Chicago.
Sam Schlessinger
Senior Vice President, General Counsel
Mr. Schlessinger has served as Senior Vice President, General Counsel of Assertio since July 2021. Mr. Schlessinger joined Assertio as Senior Corporate Counsel in May 2020 and more recently served as Vice President, Legal, overseeing SEC reporting, corporate governance, due diligence and new business development, capital markets and licensing transactions, litigation, intellectual property, and compliance.
Most recently he served in the position of Corporate Partner for Dentons, LLP where he advised public and privately held clients in mergers and acquisitions, buyouts and recapitalizations, and securities transactions. In this role, he had significant transactional experience representing private equity and other clients in acquisitions and divestitures in regulated industries, with a specialty in healthcare.
Prior to this, he was a Corporate Associate at McDermott Will & Emery LLP, where he focused on pharmaceutical monetization agreements, private equity transactions, leveraged buyouts, mergers and acquisitions, divestitures, and reorganizations.
Mr. Schlessinger holds a bachelor’s degree in mathematics from the Pomona College and a juris doctorate from the University of Illinois.
Ajay Patel
Senior Vice President, Chief Accounting Officer
Mr. Patel has served as Senior Vice President, Chief Accounting Officer of Assertio since March 2021. Mr. Patel joined Assertio as Vice President, Controller in July 2019 with responsibility for all accounting policies and practices, internal controls, income taxes and reporting.
Most recently he served in the position of Director, Technical Accounting & Accounting Policy at US Foods, where he oversaw implementation of company-wide accounting policies and helped lead acquisition financial due diligence, with a focus on quality of earnings review and accounting integration activities. Prior to this, he spent 11 years with Ernst & Young holding multiple positions of increasing responsibility in its Assurance practice leading financial statement audits of strategic key clients.
Mr. Patel holds a bachelor’s degree in finance from the University of Illinois, a master’s degree in accounting from the University of Virginia and is a certified public accountant (CPA).
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Assertio Holdings Inc (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
